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ABSTRACT
Objective: The objective of the study was to evaluate the effects of IND02 (standardized Cinnamon bark extract) supplementation for the prevention 
of side effects of cancer chemotherapy in female patients with breast cancer.
Methods: The study was conducted using double-blind, placebo-controlled design in 34 female breast cancer patients during the first 4 consecutive 
21-day cycles of the standard chemotherapy regimen. The active treatment (IND02 capsules, 400 mg, one capsule, and thrice a day) or matching 
placebo was orally administrated in randomized (1:1 ratio) patients. The efficacy outcome measures were reduction in chemotherapy-induced 
weight loss, alopecia (hair fall), and other side effects. The safety outcome measures were hematology, ECG, vital signs, adverse event monitoring, and 
laboratory safety measurements.
Results: The patients on the treatment with IND02 had shown significant protection from chemotherapy-induced severe weight loss (cachexia) and 
alopecia (reduced hair density and % hairs in the anagen phase, and increased % hairs in telogen phase) which was seen in the placebo group. IND02 
treatment was found safe and well-tolerated during the study.
Conclusion: Concomitant use of IND02 in breast cancer patients during breast cancer chemotherapy showed a clinical promise regarding efficacy and 
safety in preventing chemotherapy-induced weight loss and alopecia.
Keywords: Cinnamon bark extract, Chemotherapy-induced alopecia, Weight loss, Side effects, Breast cancer patients.
INTRODUCTION
The breast cancer is the second most common type of cancer after lung 
cancer worldwide (10.4% of all cancer incidence, both sexes counted) 
and the fifth most common cause of cancer death [1]. Breast cancer, a 
common form of cancer, usually starts in the inner lining of the milk 
ducts or lobules and goes in the uncontrolled growth stage (division 
beyond the normal limits), invasion (intrusion on and destruction of 
adjacent tissues), and sometimes results into metastasis (spread to 
other locations in the body through lymph or blood). Cancer is caused 
by external factors (tobacco, chemicals, radiation, and infectious 
organisms) and internal factors (inherited mutations, hormones, 
immune conditions, and mutations that occur from metabolism) [2].
The treatment of cancer has relied primarily on the use of various 
forms of cytotoxic chemotherapy and radiation therapy. Most 
chemotherapeutic drugs target fast-dividing cells and mitosis (cell 
division) impairment. These interventions have had profound positive 
results on many hematological malignancies and a few solid tumors, 
especially germ cell and some childhood malignancies. However, 
in most cases, the effectiveness of cytotoxic treatments has been 
limited by the side and immuno-suppression, with susceptibility to 
opportunistic pathogens [3,4] which remained as the major obstacles 
for the successful clinical use [5]. Toxicity of anticancer agents is the 
primary reason for patients to discontinue the treatment [5]. Typical 
chemotherapy side effects include severe weight loss (cachexia), 
alopecia (hair loss), nausea, vomiting, diarrhea, loss of appetite, 
mouth soars (mucositis), anemia, cardiotoxicity, hepatotoxicity, and 
nephrotoxicity.
Cachexia or severe weight loss and subsequent fatigue are the most 
debilitating side effects of most of the anticancer regimen. The primary 
causes include depression of the immune system, malnutrition, and 
dehydration caused by many chemotherapeutic agents. Chemotherapy-
induced alopecia (CIA) or hair loss is another common side effect of 
chemotherapy regimens. The likelihood of alopecia is related to the type 
of drug used and its schedule of administration. Some chemotherapeutic 
drugs that kill rapidly dividing cells cause dramatic hair loss; other 
medications may cause hair to thin. These are temporary or permanent. 
After the temporary loss, the hair usually starts to regrow after the last 
treatment, sometimes with a tendency to curl, resulting in “chemo curls.” 
Permanent hair loss can result from some standard chemotherapy 
regimens. As chemotherapy affects living, rapidly dividing cells, the hair 
loss from chemotherapy is associated with anagen effluvium (hair loss 
in the anagen or growth phase).
The nutritional approach may be the means of helping to raise cancer 
therapy to a new level of success as supplementing or supporting 
the body with natural phytochemicals not only reduce adverse side 
effects but also improve the effectiveness of chemotherapeutics [5-7]. 
However, most of the nutritional therapies have not been tested by 
rigorous clinical trials, and while some natural therapies have stood the 
test of time, very little information is available to validate their efficacy.
One such promising dietary ingredient described in many traditional 
and modern literature is Cinnamon (Cinnamomum verum and synonym 
Cinnamomum zeylanicum) bark [8-11]. Worldwide, cinnamon bark 
is used as a spice and flavoring agent due to its distinct flavor and 
aroma. The medicinal properties of cinnamon are mentioned in the 
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literature of traditional systems medicines of India, Sri Lanka, China, 
Egypt, and European countries. Moreover, cinnamon bark is a certified 
generally recognized as safe ingredient in the USA. Cinnamon bark is 
demonstrated immune stimulant and immunosuppressant activities 
depending on species, doses and nature of constituents [12,13]. 
Cinnamon-based supplements have demonstrated their ability as 
immuno-modulator [14] and anticancer [15]. Recently, sodium benzoate, 
a metabolite of cinnamon, has shown to have immunomodulatory 
activities through regulation of immune signaling pathways responsible 
for inflammation, and modulation of regulatory T cells, and cell-to-
cell contact and implicated in amelioration the disease progression 
of immune disorders [13]. Furthermore, immunomodulatory activity 
of cinnamon bark extract on multiple arms of immunity to offer 
protection against side effects of chemotherapy (cyclophosphamide) in 
the presence [12] and absence [16] of pathogenic infections has been 
reported.
The multifaceted pharmacological activity profile of cinnamon bark 
is mainly attributed to its high polyphenol content [17,18]. Cinnamon 
bark PP (polyphenols) and TAPP-CZ (TAPP, type-A proanthocyanidins 
polyphenols) based standardized cinnamon bark extract have been 
demonstrated beneficial effects against immune inflammatory 
disorders such as rheumatoid arthritis [19,20], asthma [21], and allergic 
rhinitis [22]. The preparation, standardization and pharmacological 
efficacy and safety of IND02, a standardized cinnamon bark extract 
with PP as a marker compound has been reported in animal models 
of immune inflammatory disorders such as asthma [21] and allergic 
rhinitis [23]. The past studies have confirmed the safety of oral IND02 
administration in laboratory animals [24]. The cinnamon extract has 
reported offering protection against side effects of cyclophosphamide-
induced side effects on male sexual functions in laboratory animals [16]. 
However, clinical evidence for such immunological benefits for reduction 
of chemotherapy-induced side effects is lacking. In the light of these 
findings, the present study was undertaken with an objective to explore 
potential efficacy and safety of IND02 as a nutritional adjuvant to 
prevent side effects of breast cancer chemotherapy in randomized, 
placebo-controlled, and double-blind clinical study.
METHODS
Recruitment
The sample size to achieve 80% power was calculated. A total of 
34 female patients with breast cancer undergoing chemotherapy 
before or after surgery were recruited at single center, namely, Central 
India Cancer Research Institute, Nagpur in India. The effects of IND02 
were evaluated during four chemotherapy cycles (each of 21 days) 
were followed. The treatment was initiated 7 days before the start of 
the first chemotherapy cycle with a total duration of 91 days as per 
flowchart (Fig. 1). The study was performed according to the principles 
of Good Clinical Practice, the Declaration of Helsinki, and all local laws 
and regulations about clinical studies. The trial protocol was approved 
by the Independent Ethics Committee for Human ethics requirement 
and is registered with Clinical Trial Registry of India (CTRI), New Delhi, 
India (registration No. CTRI/2012/08/002883).
The inclusion criteria consisted of the patient’s female breast cancer 
patients between the age of 18 and 70 years with confirmed primary 
carcinoma of the breast using core biopsy, needle biopsy or fine-needle 
aspiration cytology and who have undergone mastectomy and with 
indications for chemotherapy. Only patients with total leukocyte count 
≥4000/mm, platelet count ≥100,000/mm³, hemoglobin ≥10.0 g/dL 
and who are willing and able to comply with the study procedures 
and provide written informed consent to participate in the study were 
included in the study.
The exclusion criteria were as follows: (a) Patients received prior 
chemotherapy or hormonal therapy for the treatment of breast cancer 
within the past 6 months, (b) with existing mucositis or oral and throat 
pain condition before starting chemotherapy, (c) have already shaved 
the scalp hair before receiving chemotherapy, (d) have hypersensitivity 
Fig. 1: Study flowchart (CONSORT diagram)
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to the study medication, its excipients, its analogs, or any of the 
components of herbs, (e) diagnosed with active seropositive acquired 
immunodeficiency syndrome or Hepatitis B/C, (f) who are pregnant, 
lactating, pre-menopausal female patients with childbearing potential 
and/or not on contraceptives, (g) altered mental status precluding 
understanding of the informed consent process and/or completion 
of the necessary assessments, (h) with other severe diseases such as 
abnormal cardiac conditions, hepatic or renal disorder, uncontrolled 
diabetes or other medical conditions that are likely to interfere with 
the study in the investigator’s judgment, (i) have participated in other 
cancer trials in the past 30 days, and (j) who, in the investigator’s 
clinical judgment, are not suitable for this study.
Screening and randomization
Potential participants were screened, requested to attend an 
information session, informed of the trial process and were asked to 
provide their consent for trial participation. During visit 1 (screening 
visit), the medical history and demography of consenting subjects were 
taken, physical and clinical examinations and laboratory investigations 
were performed and recorded incase report forms. The medication 
was dispensed, and baseline values of outcome measures were also 
recorded. They were also randomized to 1:1 ratio to receive either 
active treatment, IND02 or placebo according to a computer-generated 
randomization list. Randomization was based on a total of 34 subjects, 
randomly allocated into two arms of equal numbers of subjects (n=17 
for each group). Both the active treatment product and the placebo 
product were enclosed in bottles containing capsules that were identical 
in the appearance and function and individually coded. Patients were 
allocated a unique randomization number.
The treatments
Female breast cancer patients undergoing chemotherapy were on the 
standard chemotherapy for four cycles of intravenous CAF regimen. 
The regimen comprises cyclophosphamide (500 mg/m2)+doxorubicin 
(adriamycin, 50 mg/m2)+5-Fluoro Uracil (500 mg/m2) on the 1st day of 
chemotherapy cycle (21-day cycle) [25]. The active treatment, IND02 
was prepared and characterized as per reported procedure [14,19]. 
IND02 is a standardized extract of C. zeylanicum bark containing 
polymeric proanthocyanidins polyphenols as a marker compound. The 
patients were instructed to consume three capsules of 400 mg of IND02 
matching placebo (di-calcium phosphate, IP grade) in a day during four 
chemotherapy cycles of CAF regimen as an adjuvant to chemotherapy.
Outcome measures
Efficacy outcome measures were a reduction in chemotherapy side 
effects caused by treatment regarding severe weight loss (cachexia), 
CIA, i.e., hair fall, mucositis, leukopenia, and anemia during each visit. 
CIA measurement was done using the TrichoScan®, a quantitative 
method, for the analysis of human hair growth and hair loss, is 
software-based that calculates hair growth parameters easily and 
rapidly. The digital images are taken from the scalp with a specially 
developed camera-optics system. TrichoScan® gives a quantitative 
result output for % anagen, telogen %, and hair densities (n/cm²). 
Mucositis was measured with the help of the WHO Oral Mucositis 
Assessment Scale [26]. The severity of nausea, vomiting, and 
diarrhea was scored based on National Cancer Institute-Common 
Toxicity Criteria version 4.0. Each patient is supplied with the diary 
in which daily record of episodes of pain, nausea, vomiting, and 
diarrhea was recorded. The diaries were collected at the last visit and 
analysis of data was done. The safety criteria were the medication 
discontinuation due to adverse events (AEs), laboratory tests and AE 
reporting of the patient with its possible association with the drug 
under study. Concomitant medication data were also recorded. The 
laboratory assessment (hematology, biochemistry, and urinalysis) was 
performed at each visit. The AE monitoring including laboratory safety 
parameters, global assessment by physician and patients, was also 
performed. Participants were monitored for protocol compliance with 
the help of a telephone or face-to-face communications.
Data analysis
The data were presented as the mean and standard deviation. The data 
were analyzed by Analysis of variance followed by unpaired t-test for 
comparisons between the groups (IND02 vs. placebo group) or paired 
t-test for comparisons within the group (end of the study vs. baseline 
values). p<0.05 was considered significant.
RESULTS
Demographics and baseline characteristics
A total of 34 patients were enrolled in the study, 17 in either arm. All the 
patients enrolled completed the study. None of the patients was dropped 
out of the study. Unpaired “t”-test of demographic parameters was found 
to be uniform as mean age, weight, heart rate, and blood pressure (systolic 
and diastolic) were not found to be significantly different (Table 1).
Effects on chemotherapy-induced weight loss
The unpaired “t”-test of body weight data of the patient from the IND02 
group was found to increased whereas that of the placebo group showed 
a decline in weight over the study period. The body weight changes (gain) 
were found to be significantly higher (p<0.05) in IND02 treated the 
patient (loss of weight) as compared placebo group at the end of cycle 2, 3, 
and 4 whereas such change was not the significant end of cycle 1 (Table 2).
Effects on CIA
Paired “t”-test of hair analysis data showed hair density of patients 
on placebo was significantly (p<0.05) reduced at the end of study 
(11.3 hairs/cm3) as compared with baseline (37.12 hairs/cm3). On 
the other hand, the reduction in hair density in IND02 treated patient 
was not significant (Table 3). Patients in the placebo group showed 
significantly (p<0.05) lower % anagen hairs at the end of study 
(39.09%) as compared to the baseline value (90.63%) whereas the 
corresponding change in IND02 treated the patient (from 74.29% 
to 50%) was not significant (Table 3). Patients in the placebo group 
showed significant (p<0.05) increase in % telogen hairs at the end of 
the study (57.27%) as compared with baseline values (10%). However, 
no significant change was observed in % telogen hairs in IND02 treated 
patients (Baseline: 21.43 %, End of study: 49.09 %) (Table 3).
Effects on chemotherapy-induced mucositis, nausea, vomiting, 
and diarrhea
No significant difference in the scores of oral mucositis, nausea, 
vomiting, and diarrhea or pain was observed in examinations during 
Table 1: Demographic and clinical characteristics of enrolled 
patients at baseline
Variable IND02 (n=17) Placebo (n=17) p-value
Age (years) 53.71±11.31 52.82±8.10 ns
Weight (kg) 58.29±11.70 64.19±13.44 ns







Data were represented as Mean value±SD and were analyzed between the 
groups by unpaired “t”-test. ns: Not significant between the groups
Table 2: Effect of treatment on change in body weights from 
baseline
Visit (end of cycle) IND02 (n=17) Placebo (n=17)
Cycle 1 ↑ 0.04±0.90 ↓ 0.15±0.57
Cycle 2 ↑ 0.38±1.15* ↓ 0.43±0.84
Cycle 3 ↑ 0.28±1.28* ↓ 0.53±1.00
Cycle 4 ↑ 0.63±1.03* ↓ 0.49±0.97
Data were represented as a change in body weight from baseline (kg) 
(mean±SD) and were analyzed by unpaired “t”‑test. *p<0.05 as compared with 
the placebo group at the respective cycle
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visits at the end of each chemotherapy cycles (data not presented). 
Similarly, no significant difference in the number of episodes of nausea 
vomiting or diarrhea was found between placebo and active treatment 
at baseline or at the end of the study (data not presented).These results 
can be explained by the same amount prophylactic treatment (for 
example, ondansetron injection and an antiemetic) that was received 
by all the patients in both the arms. Despite same dose of prophylactic 
treatment, a maximum number of vomiting episodes in placebo-treated 
patients was almost double as compared to the number of episodes 
in the IND02 group (18 vs. 10, respectively). Further, reduction in the 
number of episodes was observed in IND02 treated patients from 
10 (baseline) to 7 (end of study) whereas the maximum number of 
episodes in placebo-treated patient did not show a significant change 
from baseline during the same period (18 vs. 17).
Safety evaluation
All the patients were evaluated for safety at baseline and the end of 
each chemotherapy cycle. The safety parameter data (hematology, 
biochemistry, liver function test, and kidney function test) are presented 
in Table 4. The differences between values at baseline and the end of the 
study were found non-significant. Vital signs and physical findings of 
patients were within the normal range during the study. There were 
no deaths or serious AEs the study which confirms the excellent safety 
profile of IND02.
DISCUSSION
Cancer chemotherapy-related symptoms such as cachexia and 
resultant fatigue, malaise, loss of interest in social activities, difficulty in 
concentration and changes in sleep patterns lead to treatment delays, 
dose reductions, or termination and affect the physical, psychosocial, 
and economic aspects of quality of life [27]. Therefore, the development 
of interventions to effectively manage chemotherapy-related side 
effects is one of the significant concerns in oncology.
Nutrition intervention, together with chemotherapy, has found to 
improve outcomes in patients with pancreatic and non-small-cell lung 
cancer [28]. Immune modulation is a major element of supportive care 
for many chemotherapy regimens [29,30]. The immunomodulatory 
potential of natural products was also explored as adjuvant therapy in 
cancer patients [31]. Recently, immune-modulating diet in combination 
with chemotherapy has reported preventing cancer cachexia without 
suppressing chemotherapeutic efficacy [32]. However, clinical evidence 
for such immunological benefits for reduction of chemotherapy side 
effects is lacking. The present study is aimed to evaluate potential 
efficacy and safety of IND02, an immunomodulatory nutritional 
ingredient, as an adjuvant to chemotherapy to breast cancer patients in 
randomized, placebo-controlled, and double-blind manner.
Clinicians have long suspected the symptoms of side effects similar 
to the “sickness behavior” (triggered by the inflammatory cytokines 
interleukin 1β [IL‑1β], tumor necrosis factor α [TNF‑α], and IL‑6 
by macrophages, and other cells of the innate immune system in 
response to immune challenge) [33]. Substantial evidence implicates 
the pro‑inflammatory cytokines IL‑1β, TNF‑α, and IL‑6 in the etiology 
of chemotherapy-related cachexia and related symptoms [27]. 
Furthermore, cytokine release in response to early side effects of 
paclitaxel chemotherapy results in joint pain and flu-like symptoms [34].
Immunomodulatory effect of cinnamon bark extract is known to be 
mediated through cytokines [35] and interferon γ (IFNγ), JNK, ERK1/2, 
and STAT4, p38, but not IL-2 production in activated T cells [36]. 
The body of evidence suggested that the presence of polyphenols in 
Table 3: Effect of IND02 on CIA
Parameter IND02 (n=17) Placebo (n=17)
Baseline End of study Baseline End of Study
Hair density (hair/cm2) 44.53±16.09 21.5±23.15 ns 37.12±12.93 ↓ 11.30±12.63* 
Anagen hair (%) 74.29±33.45 50.0±45.61 ns 90.63±15.69 ↓ 39.09±42.06*
Telogen hair (%) 21.43±28.78 49.09±45.49ns 10.00±16.33 ↑ 57.27±41.01*
Data were represented as parameter Mean±SD and were analyzed by paired “t”‑test for each parameter. ns: Not significant, *p<0.05 as compared with baseline for 
respective parameter. ↑ indicate a significant increase and ↓ indicate a significant decrease as compared with baseline values
Table 4: Hematology and biochemistry at baseline and end of treatment (safety)
Parameter IND02 (n=17) Placebo (n=17)
Baseline End of study Baseline End of Study
Hematology
RBC Count (million/mm3) 3.97±0.47 ↑ 4.06±0.35 4.36±0.47 ↓ 4.20±0.40
Platelet count (/mm3) 282823.53±76619.38 261823.53±88115.15 242529.41±39721.09 283294.12±82815.13
Total WBC (/mm3) 7741.18±1736.40 6994.12±2801.67 7711.76±2102.94 6200.0±2855.91
Basophil (/mm3) 00.00±0.00 00.00±0.00 0.12±0.49 0.00±0.00
Eosinophil (/mm3) 2.88±0.99 3.06±0.90 3.53±1.23 3.53±1.74
Lymphocytes (/mm3) 27.82±6.89 33.06±9.25 31.41±6.87 31.88±11.36
Monocytes (/mm3) 2.12±0.33 2.06±0.90 2.24±0.56 2.24±0.97
Neutrophils (/mm3) 68.12±6.36 61.82±9.58 62.88±7.33 62.24±12.42
Hemoglobin (%) 11.276±0.82 11.300±0.91 11.788±0.81 11.294±1.173
Biochemistry
ALP (IU/L) 98.19±25.39 93.36±24.24 85.77±14.46 80.93±12.58
ALT (IU/L) 28.32±18.15 22.55±5.78 21.36±4.78 20.53±5.96
AST (IU/L) 33.22±20.63 24.59±5.73 26.34±6.03 23.74±7.28
Bilirubin direct (mg/dl) 0.31±0.07 0.31±0.12 0.31±0.11 0.29±0.08
Bilirubin total (mg/dl) 0.70±0.11 0.72±0.16 0.69±0.10 0.67±0.11
Serum creatinine (mg/dl) 0.83±0.26 0.82±0.11 0.77±0.25 0.83±0.15
Urea (mg/dl) 24.39±8.04 22.20±4.51 24.28±8.97 21.29±5.23
Uric acid (mg/dl) 3.78±1.39 3.91±0.67 4.01±0.71 4.22±1.32
The data are represented as the Mean±Standard deviation. Data were analyzed by paired “t”-test for each parameter within the group. No significant changes for any of 
the parameters within the groups (baseline vs. the end of study). RBC: Red blood cells, WBC: White blood cells, ALP: Alkaline phosphatase, ALT: Alanine transaminase, 
AST: Aspartate aminotransferase
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cinnamon bark extract is responsible for anti-inflammatory effects 
through TNF‑α gene modulation through NF‑κB and mitogen‑activated 
protein kinase [37]. Recently, the anti-inflammatory effects of a 
polyphenol fraction of cinnamon bark [19] and TAPP [20] in animal 
models of inflammation through cytokine (IL‑2, IL‑4, and IFNγ) 
inhibition have been reported. Therefore, the beneficial effects of 
IND02 on chemotherapy-induced cachexia in the present study can be 
attributed to cytokine inhibition action by the marker compound, TAPP 
from a cinnamon bark extract.
Chemotherapy is generally regarded as an immune suppressant if 
moderate cytotoxic doses are applied. However, the therapeutic effect 
of chemotherapy may, in turn, increase immunity due to the partial 
elimination of suppressive factors from tumor cells. Therefore, the 
immune function is affected by chemotherapy in the negative [38] and 
positive [39] manner. Therefore, a combination of chemotherapeutic 
and immunotherapeutic approaches are suggested in cancer 
treatment. Furthermore, immunity enhancement acts synergistically 
when chemotherapy has a positive effect on immunity [40]. The 
beneficial effect of prevention of weight loss as observed by IND02 
supplementation with standard chemotherapy regimen in breast 
cancer patients during the present study is supporting the notion of a 
combination approach.
CIA affects various aspects of cancer patient’s quality of 
life [41] and frequently ranked among top distressing/troublesome 
side effects of chemotherapy especially in female breast cancer 
patients [42,43] to the extent of refusal to chemotherapy [42,44]. 
The need to improve the management and measurement of CIA is 
emphasized in recent literature [45]. In the present study, the impact 
of TAPP-CZ supplementation on CIA using the modern, quantitative and 
precise technique (TrichoScan®) to measure hair density, and % hairs 
in anagen (growth) and telogen (fall) phases of patients as a measure 
of alopecia were evaluated. The outcome measures of CIA were found 
to be unchanged in IND02 supplementation group whereas placebo 
showed alopecia (decrease in hair density, % anagen hairs, and 
increase in % telogen hairs) and indicates beneficial effects of IND02 
supplementation in CIA in breast cancer patients. To the best of our 
knowledge, our study is first clinical study to use such quantitative 
measures of CIA as an outcome measure.
Many anticancer drugs attack rapidly dividing cells, including not only 
malignant cells but also in hair follicle cells, and induce alopecia [46]. 
The role of apoptosis in CIA is also established [46]. Recently, cinnamon 
bark extract demonstrated its ability to promote apoptosis pathway and 
selective killing of tumor cells [47] in addition to suppression of tumor 
progression [48]. The proanthocyanidins content from grape seeds is 
known to demonstrate anticancer effects through apoptosis induction 
in many cancer cells including highly metastatic breast carcinoma 
cells [49,50]. Therefore, apoptosis-promoting effects of procyanidin 
content (a marker compound) of IND02 may be responsible for 
beneficial effects of IND02 supplementation in the prevention of 
alopecia. However, additional studies may be required to confirm the 
mechanism of the action.
CONCLUSION
Standardized cinnamon bark extract was found to be beneficial as an 
adjuvant in preventing breast cancer chemotherapy-induced weight 
loss and alopecia.
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